Effect of MetS* on Cognitive Performance and Physical Activity (Metabolic Syndrome)

Last updated: January 11, 2024
Sponsor: Istanbul University - Cerrahpasa (IUC)
Overall Status: Active - Recruiting

Phase

N/A

Condition

Metabolic Syndrome

Metabolic Disorders

Diabetes Prevention

Treatment

assessment of cognitive performance

Clinical Study ID

NCT05702437
3274238910
  • Ages 18-50
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Metabolic syndrome (MetS) increases the risk of developing diabetes and cardiovascular disease risk factors that are linked with each other, which is a metabolic dysfunction, which contains a combination of multiple.

It is known that METS plays a role in the development of many diseases such as cardiovascular diseases, stroke, cancer, Alzheimer's. Studies have revealed that neuroinflammation, oxidative stress, abnormal lipid metabolism and impaired vascularization, which play a role in the pathogenesis of MetS, affect the structure of the brain and cognition. Atherosclerosis of the carotid artery, increased brain atrophy and white matter damage are potential explanatory mechanisms that lead to an impact on cognitive skills in patients with MetS. In addition, the existence of MetS components such as obesity, diabetes, hypertension alone also negatively affects cognitive functions, and the level of cognitive influence also increases as the number of components an individual has increases.

The literature reports that learning, executive functions, processing speed, attention/working memory and global cognitive functions are affected in individuals with MetS, but no consensus has been reached on this issue. Some studies say that MetS causes a significant decrease in cognitive functions, while some studies indicate that this difference is not significant.

The aim of our study is to proof the relationship between MetS and cognitive functions with metabolic syndrome components.

H1:There is a relationship between the MetS and cognitive functions.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • being between the ages of 18-50
  • Having been educated for at least 5 years and know how to read and write
  • Having been diagnosed with MetS by meeting 3 of the NCEP-ATP III criteria (forparticipants in the MetS Group)
  • To have a biochemistry test performed within the last 6 months (for the Healthy Group)
  • Not having any MetS components (For the Healthy Group)

Exclusion

Exclusion Criteria:

  • Having any neurological, psychiatric and psychological diseases that may affectcognitive status
  • Taking antipsychiatric medication
  • The presence of any visual-auditory intellectual disability
  • Having undergone bariatric surgery

Study Design

Total Participants: 82
Treatment Group(s): 1
Primary Treatment: assessment of cognitive performance
Phase:
Study Start date:
February 20, 2023
Estimated Completion Date:
May 31, 2025

Study Description

Voluntary participants who have been diagnosed with MetS and agreed to voluntary health subjects will be included in the study. Signed voluntary consent will be obtained from participants. Participants will be divided into two groups. There will be individuals diagnosed with MetS in the intervention group and healthy individuals who do not have any problems in the control group.

Connect with a study center

  • Bezmialem Vakif University

    Istanbul, 34093
    Turkey

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.